Loading, Please wait ...

Teva Pharmaceutical Industries Limited

Please contact us if you would like to upgrade your account to include access to financial models

Please contact us if you would like to upgrade your account to include short term strategies for this stock.

TEVA.O

ISIN: US8816242098
SEDOL: 2883878

Rating:

BUY

Target Price:

59.44 USD

Investment Horizon:

6 to 12 months
5th May 2009 View Report   Download

1Q 09 News Alert

Teva Pharmaceutical Industries Limited’s (Teva) net sales and operating income was below our estimates in 1Q 09. However, operating and net margin outperformed our expectations in 1Q 09. 1Q 09 results also include the results of Barr Laboratories Inc. (Barr). Going forward, we expect continued revenue performance from the company’s key products; Copaxone and Azilect, coupled with improved revenue performance from its generic products....

9th Apr 2009 View Report   Download

4Q 08 & FY 2008 Update Report

Teva Pharmaceutical Industries Ltd. (Teva) is expected to further enhance its penetration levels in the US market given the strong focus of the new US government towards reducing healthcare expenditure. Teva has recently secured new contracts in Germany, coupled with an acquisition in Spain, resulting in the company to gain a significant market share in the European region. The acquisition of Barr Pharmaceuticals Inc....

17th Feb 2009 View Report   Download

4Q 08 & FY 2008 News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Teva Pharmaceutical Industries Limited’s (Teva) net sales was in line with our estimates, while operating income and net income were higher than our estimates in 4Q 08. For FY 2008, net sales and operating income were in line with our estimate, while net income was marginally higher than our estimate in FY 2008. Going forward, we expect continued revenue performance from the company’s key products; Copaxone and Azilect, coupled…

9th Feb 2009 View Report   Download

3Q 08 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

We maintain our positive outlook for Teva’s plans to expand its presence in the Japanese generic market (the second largest pharmaceutical market after the US) with strategic partnership with Kowa Company Ltd. announced on 24 September 2008, which is expected to take effect from FY 2009. According to IMS Health, the generics market accounted for only 5.7% in value and 16.9% in volume of the total Japanese pharmaceutical market in…

17th Nov 2008 View Report   Download

3Q 08 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

Teva Pharmaceutical Industries Ltd. (Teva) reported strong y-o-y growth in net sales, primarily driven by strong growth of its key products Copaxone and Azilect in 3Q 08. However, net sales were below our estimates in 3Q 08. Going forward, we expect the company’s key products, such as Copaxone and Azilect, to support top-line performance. Furthermore, the acquisition of Barr Pharmaceuticals Inc. (Barr), which is the fourth largest…